Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease

Hypertension Research

Volumn 32, Issue 4, 2009, Pages 270-275

  Abe, Masanori ^a   Okada, Kazuyoshi ^a   Maruyama, Takashi ^a   Maruyama, Noriaki ^a   Matsumoto, Koichi ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blocker; Benidipine; Chronic kidney disease; Proteinuria

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BENIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OLMESARTAN; TELMISARTAN;

AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG ERUPTION; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; LIVER DISEASE; MALE; OPEN STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RENAL PROTECTION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URINARY FREQUENCY;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTECTIVE AGENTS; PROTEINURIA;

EID: 70350045748     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.11     Document Type: Article

References (29)

1. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. The modification of diet in renal disease study group: blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123: 754-762. (Pubitemid 27074731)
2. De Leeuw PW, Thijs L, Birkenhager WH, Voyaki SM, Efstratopoulos AD, Fagard RH, Leonetti G, Nachev C, Petrie JC, Rodicio JL, Rosenfeld JJ, Sarti C, Staessen JA, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators, Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13: 2213-2222.
3. Marin R, Gorostidi M, Fernandez-Vega F, Alvarez-Navascues R. Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. Kidney Int 2005; 99: S52-S56. (Pubitemid 44324687)
4. Viberti G, Wheeldon MN, MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators, Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group, Renoprotective effect of angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
6. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition, a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252. (Pubitemid 38129085)
7. Weidmann P, Boehlen LM, Courten M. Effects of different antihypertensive drugs on human proteinuria. Nephrol Dial Transplant 1993; 8: 582-584. (Pubitemid 23231138)
8. Lavermann GD, Henning RH, De Jong PE, Navis G, Zeeuw D. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001; 38: 1381-1384. (Pubitemid 34193131)
9. Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for Management of Hypertension (JSH 2004), Hypertens Res 2006; 29(Suppl): S1-S105.
10. Sheinfield GR, Bakris GL, Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients, Am J Hypertens 1999; 12: 80-85.
11. Waeber B. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. J Hypertens 2006; 24: 19-27. (Pubitemid 44336815)
12. 2+ channels in renal microcirculation. J Pharmacol Sci 2005; 99: 221-227.
13. Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T. Renal-protective effect of T- and L-type calcium channel blockers in hypertensive patients: an amlodipine-to-benidipine changeover (ABC) study, Hypertens Res 2007; 30: 797-806. (Pubitemid 47578241)
14. 2+ channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999; 291: 464-473.
15. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 1996; 19: 31-36. (Pubitemid 26134958)
16. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshlki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators, Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543-1549.
17. Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H, Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621-626. (Pubitemid 47278320)
18. Morikawa T, Okumura M, Konishi Y, Okada N, Imanishi M. Effects of benidipine on glomerular hemodyanamics and proteinuria in patients with nondiabetic nephropathy. Hypertens Res 2002; 25: 571-576.
19. Saito F, Fujita H, Takahashi A, Ichiyama I, Harasawa S, Oiwa K, Takahashi N, Otsuka Y, Uchiyama T, Kanmatsuse K, Kushiro T. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria, Hypertens Res2007; 30: 39-47.
20. The Japanese Society of Nephrology, New eGFR equation for Japanese, Available at: http://www.jsn.or.jp/jsn-new/eng/index-e.html; accessed June 30, 2008.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
22. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension, J Hypertens 2003; 21: 1011-1053.
23. Kim-Mitsuyama S, Izumi Y, Izumiyz Y, Yoshida K, Yoshiyama M, Iwao H. Additive beneficial effects of the combination of calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model. Hypertens Res 2004; 27: 771-779. (Pubitemid 40045517)
24. Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, Yoshii T, Oshita A, Mogi M, Horiuchi M. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens 2005; 23: 1383-1389. (Pubitemid 40933959)
25. Maneia G, Seravalle G, Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists, Am J Hypertens 2003; 16: 1066-1073. (Pubitemid 37500805)
26. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-151.
27. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V. Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology, 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European society of Cardiology (ESC), J Hypertens 2007; 25: 1105-1187.
28. Yue W, Kimura S, Fujisawa Y, Tian R, Li F, Rahman M, Nishiyama A, Fukui T, Abe Y. Benidipine dilates both pre- and post-glomerular arteriole in the canine kidney. Hypertens Res 2001; 24: 429-436. (Pubitemid 32791819)
29. Kawata T, Hashimoto S, Koike T. Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats, J CardioiVasc Pharmacol 1997; 30: 431-436. (Pubitemid 27527577)